Skip to main content
Print Page    E-mail Page    RSS    E-mail Alerts    Tearsheet 

Investors & Media

Corporate Profile

Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics, that are designed to restore health by repairing the function of a dysbiotic microbiome. The Company’s lead product candidate, SER-109, is intended to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon, and, if approved by the FDA, could be a first-in-field drug. Using its... More

Recent NewsMore
Seres Therapeutics to Present at the Stifel 2018 Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 9, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that it will present at the Stifel 2018 Healthcare Conference in New York, NY on Tuesday, November 13th at 9:30 a.m. ET. A live audio webcast of the presentation will be available under the “Investors and Media” section of Seres’ website. A replay will become available approximately one hour after the event and will be archived f... 
Seres Therapeutics Reports Third Quarter Financial Results and Provides Operational Updates
- Kevin Horgan, M.D. an accomplished drug developer and immunology expert, hired as Chief Medical Officer - - Planning for two new microbiome clinical studies in ulcerative colitis and metastatic melanoma; Company expects to receive $40M in payments from Nestlé Health Science with SER-287 Phase 2b study start - - Conference call at 8:30 a.m. ET today - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 8, 2018-- Seres Therapeutics,... 
Seres Therapeutics to Host Third Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on November 8, 2018
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 5, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on November 8, 2018 at 8:30 a.m. ET to discuss third quarter 2018 results and provide a general business update. To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 9877087. To j... 
Download DocumentationCorporate Presentation

There are currently no upcoming events scheduled.
Stock Quote
 - 0.3 (4.48%)
12/14/18 4:00 p.m. ET
Refresh quote
E-mail Alerts
Sign up to receive e-mail alerts whenever Seres Therapeutics, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Request Information

Obtain investor relations information by contacting us.

Data provided by Nasdaq. Minimum 15 minutes delayed.